Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease) – Drugs In Development, 2024 report and make more profitable business decisions.
Hereditary hemorrhagic telangiectasia (HHT) is also known as Osler-Weber-Rendu disease. It is an autosomal dominant disorder characterized by multiple mucocutaneous telangiectasias. These telangiectasias represent small arterio-venous malformations that frequently tend to bleed, causing the patient a significant amount of distress in their daily lives. Symptoms may include nose bleeds, gastrointestinal (GI) bleeds, and iron deficiency anemia.
The Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease) drugs in development market research report provide comprehensive information on the therapeutics under development for Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 8 molecules, with 8 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Boehringer Ingelheim International GmbHFujimoto Pharmaceutical Corp
Hemab ApS
Laboratoires Delbert
Laekna Therapeutics Shanghai Co Ltd
PlumeStars Srl
Starfish Innovations
Vaderis Therapeutics AG
Table of Contents
Table
Figures
Frequently asked questions